Virology Follow up Study in Subjects Previously Treated With Telaprevir
Public ClinicalTrials.gov record NCT00916474. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
EXTEND: A 3-Year, Virology Follow up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time.
Study identification
- NCT ID
- NCT00916474
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 408 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2009
- Primary completion
- Nov 30, 2013
- Completion
- Nov 30, 2013
- Last update posted
- Feb 26, 2014
2009 – 2013
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama | Birmingham | Alabama | — | — |
| California | Coronado | California | — | — |
| California | Los Angeles | California | — | — |
| California | San Francisco | California | — | — |
| Colorado | Denver | Colorado | — | — |
| Colorado | Englewood | Colorado | — | — |
| Florida | Gainsville | Florida | — | — |
| Florida | Jacksonville | Florida | — | — |
| Florida | Miami | Florida | — | — |
| Georgia | Altanta | Georgia | — | — |
| Maryland | Baltimore | Maryland | — | — |
| Massachusetts | Boston | Massachusetts | — | — |
| Michigan | Novi | Michigan | — | — |
| Missouri | St Louis | Missouri | — | — |
| New Mexico | Albuquerque | New Mexico | — | — |
| New York | Manhasset | New York | — | — |
| New York | New York | New York | — | — |
| North Carolina | Chapel Hill | North Carolina | — | — |
| North Carolina | Durham | North Carolina | — | — |
| Ohio | Cincinnati | Ohio | — | — |
| South Carolina | Columbia | South Carolina | — | — |
| Texas | Houston | Texas | — | — |
| Texas | San Antonio | Texas | — | — |
| Virginia | Fairfax | Virginia | — | — |
| Virginia | Falls Church | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00916474, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 26, 2014 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00916474 live on ClinicalTrials.gov.